Ivermectin in Cancer – Research Insights & Emerging Use (2024)

🧬 Introduction

Ivermectin, a well-known antiparasitic drug widely used to treat parasitic infections such as onchocerciasis and strongyloidiasis, has unexpectedly emerged as a candidate for cancer research. Over the past few years, scientific curiosity has grown around Ivermectin’s potential anti-cancer effects, spurred by promising preclinical data. Though not yet a part of mainstream oncology, Ivermectin is being actively evaluated in various laboratory studies and experimental models. This article delves into its mechanisms, research progress, and the global attitude toward its off-label use in cancer care as of 2024.

---

⚙️ How Might Ivermectin Work Against Cancer?

Researchers suggest that Ivermectin may interfere with various molecular and cellular pathways involved in tumor growth:

• Inhibition of the PAK1 Pathway: This pathway plays a significant role in cancer cell growth and survival. Ivermectin’s ability to suppress PAK1 suggests a potential for halting tumor progression.
• Induction of Apoptosis: Ivermectin may promote programmed cell death in cancer cells, effectively reducing tumor size in preclinical models.
• Immune Modulation: The drug might enhance the body’s immune response, enabling T-cells to detect and destroy cancer cells more efficiently.
• Suppression of WNT-TCF Signaling: Overactivation of this pathway is linked to many cancer types. Ivermectin’s suppression of WNT signaling could inhibit tumor growth.
• Anti-angiogenesis: By reducing the formation of new blood vessels, it may starve tumors of nutrients and oxygen, limiting their spread.

---

🔬 Key Research Studies & Findings

Here are notable studies exploring Ivermectin’s anti-cancer potential:

1. Zhang et al. (2019, Biochemical Pharmacology):
   Found that Ivermectin suppressed colorectal cancer cell growth by disrupting cell cycle regulation.
2. Li et al. (2020, Frontiers in Pharmacology):
   Demonstrated that Ivermectin induced cell death in lung and breast cancer cell lines.
3. Gao et al. (2021):
   Found Ivermectin targets the mTOR signaling pathway, limiting cancer cell viability.
4. NIH PubMed Database:
   Over 100+ publications mention Ivermectin’s emerging oncological applications.

🔎 Note: Most studies are preclinical (lab-based) or animal trials. Human clinical trials are still limited or under evaluation.

---

🛑 Is Ivermectin Approved for Cancer Treatment?

No. As of 2024, it is not approved by the FDA, EMA, or WHO for use in cancer therapy. Any use in oncology is considered off-label and should only be pursued under research supervision or clinical trial conditions.

---

🌍 Where Is Ivermectin Being Considered in Oncology?

Despite the lack of formal approval, interest in ivermectin for cancer is increasing in several parts of the world:

• India & Latin America – Some integrative oncology clinics are including ivermectin in off-label protocols, often alongside natural supplements.
• Eastern Europe – Advocacy groups are calling for more trials and compassionate use access.
• Africa & Southeast Asia – A few NGOs are exploring its use due to affordability and accessibility.

⚠️ These uses are not standard and should be approached with caution.

---

📦 Looking to Source Ivermectin for Research or Hospital Use?

Globalstar offers WHO-GMP certified Ivermectin tablets (3 mg, 6 mg, 12 mg) for hospitals, research institutions, and clinical trial use globally. We support:

• Third-party labeling
• Dossier documentation
• COA, COPP, and stability reports
• Clinical trial formulation batches

Visit our Iverstar page.